Last reviewed · How we verify
Efficacy of ceftaroline
Ceftaroline is a fifth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Ceftaroline is a fifth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Community-acquired bacterial pneumonia (CABP), Acute bacterial skin and skin structure infections (ABSSSI), Methicillin-resistant Staphylococcus aureus (MRSA) infections.
At a glance
| Generic name | Efficacy of ceftaroline |
|---|---|
| Sponsor | Albany Medical College |
| Drug class | Fifth-generation cephalosporin |
| Target | Bacterial penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ceftaroline fosamil is a prodrug that is converted to ceftaroline, which has enhanced activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) compared to earlier-generation cephalosporins. It binds to bacterial penicillin-binding proteins and inhibits cross-linking of peptidoglycan, leading to cell wall disruption and bacterial death. The drug has broad-spectrum activity against both gram-positive and gram-negative organisms.
Approved indications
- Community-acquired bacterial pneumonia (CABP)
- Acute bacterial skin and skin structure infections (ABSSSI)
- Methicillin-resistant Staphylococcus aureus (MRSA) infections
Common side effects
- Diarrhea
- Nausea
- Phlebitis at infusion site
- Hypersensitivity reactions
Key clinical trials
- Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients (PHASE4)
- Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (PHASE2)
- Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia (PHASE3)
- Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. (PHASE3)
- Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections (PHASE3)
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (PHASE3)
- Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efficacy of ceftaroline CI brief — competitive landscape report
- Efficacy of ceftaroline updates RSS · CI watch RSS
- Albany Medical College portfolio CI